BioInsights - Addressing current challenges in lentiviral vector purification and associated analytics
Sep
20
2022
On demand

Addressing current challenges in lentiviral vector purification and associated analytics

Sponsor
Addressing current challenges in lentiviral vector purification and associated analytics

As more and more engineered cell therapy products that utilize lentiviral (LV) vectors in their manufacture reach the market, the sector’s focus is sharpening around optimizing LV downstream processing. Given the significant contribution that LV vectors make to the overall cost of goods of these cell therapy products, and the importance of maximizing quality for patient safety and regulatory CMC purposes, it is imperative to maximize downstream purification efficiency and vector recovery, and to be able to harness the available analytical toolkit to demonstrate vector quality.

Here, we convene a panel of LV downstream process experts to explore current issues in the field, and discuss how they can be overcome utilizing the available LV purification and analytics toolkit.

Bryan Zee

Associate Scientist, Gene Delivery Process & Analytical Development, Juno Therapeutics, a Bristol Myers Squibb Company

Bryan started his purification career at Amgen’s PD group where he developed several clinical stage biologics and handled a myriad of modalities such as mAbs, bispecifics, and Fc-fusion proteins. Since 2019 he’s been at BMS’s viral vector PD department where he has developed BMS’s LVV purification platform and AAV purification platform.

Anindya Dasgupta

Director, Vector Development, Expression Therapeutics

Anindya is the director of vector development at Expression Therapeutics. He obtained his PhD from University of South Carolina, USA. His post-doctoral training and research associateship at the school of medicine, Emory University, Atlanta, USA, were focussed on the evaluation of novel anti-cancer therapies and the development of strategies for expansion and lentivirus based bioengineering of yo T cells in serum free media . Anindya is a co-inventor of a patent on anti-cancer strategy. At his recent role at Cincinnati Children’s Hospital Medical Centre he led vector development to manufacture high titer lentiviral vectors.


SPEAKERS

Bryan Zee
Bryan Zee
Associate Scientist, Juno Therapeutics, Inc.
Anindya Dasgupta
Anindya Dasgupta
Director of GMP at Expression

You might also like

Aldevron case study: validation of mRNA concentration determination using variable pathlength spectroscopy

Aldevron case study: validation of mRNA concentration determination using variable pathlength spectroscopy

Joe Ferraiolo, Travis Alvine
12 July 2023
in 38
Days
Register
Addressing regulatory guidance for HEK293 cells and AAV-based therapeutic manufacturing

Addressing regulatory guidance for HEK293 cells and AAV-based therapeutic manufacturing

Michael Brewer
29 June 2023
in 25
Days
Register
Accelerate your AAV process development with a new-wave analytical tool

Accelerate your AAV process development with a new-wave analytical tool

Andreja Gramc Livk
28 June 2023
in 24
Days
Register
Scalable production of AAV from shake flasks to 1,000 L single use bioreactors using the Gibco™ CTS™ AAV-MAX Production System

Scalable production of AAV from shake flasks to 1,000 L single use bioreactors using the Gibco™ CTS™ AAV-MAX Production System

Jonathan Zmuda
20 June 2023
in 16
Days
Register
Overcoming upstream and downstream process barriers for large scale AAV production

Overcoming upstream and downstream process barriers for large scale AAV production

B Woo, A Miller, J Zmuda
15 June 2023
in 11
Days
Register